PRESS RELEASE published on 07/03/2024 at 08:12, 2 years ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 2 years ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 2 years ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 2 years ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 2 years 1 month ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 2 years 1 month ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 2 years 1 month ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 2 years 1 month ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 2 years 2 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 2 years 2 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 07/21/2026 at 23:00, 2 hours 27 minutes ago Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details
Published on 07/21/2026 at 22:30, 2 hours 57 minutes ago Fermi Announces First Siemens Turbines Arrive at Port of Houston
Published on 07/21/2026 at 22:30, 2 hours 57 minutes ago Matador Technologies Announces Management Transition
Published on 07/21/2026 at 22:15, 3 hours 12 minutes ago Vanta Announces Updated Time for Participation in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22, 2026, at 12:00 p.m. ET
Published on 07/21/2026 at 22:00, 3 hours 27 minutes ago Redwood AI Announces Closing of $3.5 Million Private Placement
Published on 07/22/2026 at 01:05, 22 minutes ago Quantinuum and SoftBank Corp. Publish Joint White Paper on Scaling Practical Quantum Computing Use Cases Toward the Fault-Tolerant Era
Published on 07/21/2026 at 22:30, 2 hours 57 minutes ago Strong second quarter: GEA raises full-year guidance for 2026
Published on 07/21/2026 at 22:16, 3 hours 11 minutes ago EQS-Adhoc: GEA Group Aktiengesellschaft: Preliminary numbers for Q2 2026 exceed market expectation - increase of guidance for fiscal year 2026
Published on 07/21/2026 at 18:50, 6 hours 37 minutes ago Soapeya, a DN Group AG Portfolio Company, Earns Top "Excellent" Rating from Dermatest and Proves Successful in Field Use in Ghana
Published on 07/21/2026 at 18:15, 7 hours 11 minutes ago EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/20/2026 at 18:20, 1 day 7 hours ago Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day 7 hours ago Reporting on share buyback transactions carried out between July 8 and July 9, 2026
